Im­muno­vant post­pones tri­al read­outs for its late-stage FcRn drug as it pri­or­i­tizes an­oth­er

Im­muno­vant has reshuf­fled plans for two of its an­ti-FcRn an­ti­body drugs.

The com­pa­ny has de­layed clin­i­cal read­outs by sev­er­al months for its late-stage FcRn in­hibitor …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER